A Phase 1, Non-randomized, Open-label, Single-dose, Parallel Cohort Study to Compare the Pharmacokinetics of PF-06882961 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment
Latest Information Update: 25 Mar 2024
At a glance
- Drugs Danuglipron (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Pfizer
- 13 Jan 2022 Status changed from recruiting to completed.
- 05 Mar 2021 Planned End Date changed from 25 Feb 2022 to 27 Feb 2022.
- 05 Mar 2021 Planned primary completion date changed from 25 Feb 2022 to 27 Feb 2022.